Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
NCT03883776Phase 1Completed
- Sponsor
- UZ Leuven
- Start
- Apr 2019
- Primary completion
- Oct 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-AlF-NOTA-octreotide in neuroendocrine tumors (NETs), sponsored by UZ Leuven. Primary endpoint: Potential of Al18F-NOTA-octreotide as somatostatin receptor PET imaging tracer at 1 year. Started Apr 2019; status: completed.
02
Drugs
18F-AlF-NOTA-octreotide
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03883776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03883776.